Based on our current knowledge of NASH and on the lack of approved pharmacological therapies, the present study strongly suggests that TG68 represents an innovative hepatospecific THRβ agonist with no detectable toxicity, and, consequently, an attractive candidate for the treatment of NASH. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.